Eleven patients with p thalassemia major were entered into the trial of the oral chelator 1.2-dimethyl-3-hydroxypyrid-4-one (L1). Their ages ranged from 17 to 26 years (mean & SD, 22.3 & 2.7). Six were male and five were female. L1 was administered at an initial daily dose of 42.5 to 60 mg/kg as a single dose. After 4 weeks, the dose was increased to 85 to 119 (102 f 10.7) mg/kg for 191 to 352 days divided into either two or four doses daily, except for one patient who developed agranulocytosis after 11 weeks and was taken off the trial. Initial serum ferritin values in the remaining 10 patients ranged between 1.000 and 9,580 (5,549 f 3,333) pg/L and at end of the trial their mean serum ferritin was significantly lower (4,126 & 2,278; P e .05 using the paired t-test). Urinary iron excretion at a daily dose of 85 to 119 mg/ kg administered as two divided doses ranged between 0.14 and 0.82 (0.44 2 0.26) mg/kg/24 h. In three patients, the four doses per day schedule caused substantially more iron excretion than the same total dose divided into two. During the course of the trial, several possible adverse effects have been encountered. One patient (female, aged 20) developed agranulocytosis 11 weeks after starting treatment and 6 HE CHRONIC transfusion program in patients with p T thalassemia major (TM) is associated with iron overload and widespread organ damage. Desfemoxamine (DFX) has proved t o be a highly effective and reasonably safe iron chelator and with the introduction of chronic subcutaneous administration there has been a decline in morbidity and mortality in those on regular chelation.',* However, the use of DFX is hindered by two major obstacles: high cost and poor compliance. Therefore, there is an urgent need for an orally acting iron chelator that is safe and inexpensive.
t-test). Urinary iron excretion at a daily dose of 85 to 119 mg/ kg administered as two divided doses ranged between 0.14 and 0.82 (0.44 2 0.26) mg/kg/24 h. In three patients, the four doses per day schedule caused substantially more iron excretion than the same total dose divided into two. During the course of the trial, several possible adverse effects have been encountered. One patient (female, aged 20) developed agranulocytosis 11 weeks after starting treatment and 6 HE CHRONIC transfusion program in patients with p T thalassemia major (TM) is associated with iron overload and widespread organ damage. Desfemoxamine (DFX) has proved t o be a highly effective and reasonably safe iron chelator and with the introduction of chronic subcutaneous administration there has been a decline in morbidity and mortality in those on regular chelation.',* However, the use of DFX is hindered by two major obstacles: high cost and poor compliance. Therefore, there is an urgent need for an orally acting iron chelator that is safe and inexpensive.
Many compounds have been developed, of which 1,2-dimethyl-3-hydroxypyrid-4-one (Ll) has now been tested in several clinical trials3-I1 and shown to be effective. This present trial was designed to further assess the long-term effectiveness of L1 in patients with TM and the incidence of possible adverse effects.
PATIENTS AND METHODS
Approval for the trial was obtained from the Royal Free Hospital's Ethical Committee. Eleven patients were initially entered into the trial after giving their written informed consent. Details of their initial clinical findings and doses of L1 are given in Table 1 . One patient was taken off the trial after 11 weeks because of the development of agranulocytosis; the long-term follow-up data, therefore, refer to the remaining 10 patients. Initial investigations included detailed clinical examination, full blood count (FBC), blood urea and electrolyte (U&E), creatinine, liver function tests (LFTs), and tests of iron status, including serum ferritin, serum iron, total iron binding capacity (TIBC), non-transferrinbound iron (NTBI), and 24-hour urinary iron in response to DFX or L1. Other tests included prothrombin time (PT), partial thromboplastin time (PTI'K), direct antiglobulin test, leukocyte ascorbate, electrocardiogram (ECG), multigated scintigraphy (MUGA scan) at rest and with cold stress, retinal function tests (visual acuity, electrooculogram, electroretinogram and pattern, visually evoked responses, and color vision), audiogram, serum Igs, T-cell subsets (CD4/CD8 ratio), rheumatoid factor (RhF), antinuclear weeks after beginning treatment with a daily dose of 105 mg/ kg. This patient's neutrophil count recovered spontaneously 7 weeks after the discontinuation of L1. A decrease in serum zinc levels to subnormal levels was observed in four patients with symptoms of dry skin, with an itchy scaly rash in two that was associated with low serum zinc levels that responded to zinc therapy. Urinary zinc levels ranged from 4.7 to 23.4 (13 f 5.5) pmo1/24 h and were above 9 pmo1/24 h (upper limit of normal) in eight patients. Mild nausea occurred in three patients and transient diarrhea in a fourth. Mild musculoskeletal symptoms occurred in three patients but settled without discontinuation of L1 therapy in two and with temporary discontinuation of L1 in the third. A transient increase in serum aspartate transaminase was also noted in five patients, but serum aspartate transaminase levels subse- This was administered as a single daily dose for 4 weeks and then twice daily or at the same total dose administered four times daily. All doses were taken on an empty stomach and at least 1 hour before eating. No food was taken for at least 1 hour after taking the drug. Vitamin C was initially discontinued on all patients, except cases 10 and 11. Those who had a decrease in leukocyte ascorbate to less than 23 pg/103 white blood cells (WBC; normal range, 23 to 51) were restarted on vitamin C (200 mg daily) with breakfast given separate from L1. Patients 10 and 11 had low pretrial vitamin C levels and were therefore kept on vitamin C 200 mg daily with breakfast.
RESULTS
In general, the drug was well accepted and compliance was apparently excellent as assessed by the patient's history, parental evidence, and useage of capsules provided in just-sufficient quantities between hospital visits. No change was noted in cardiac function, blood pressure, renal function, lipid profile, and hormone levels. No neurologic, retinal, or audiometry changes were shown throughout the trial.
UIE varied considerably from day to day in each patient ( Table 2 ). The mean excretion in response to 85 to 119 mg/kg daily administered as two divided doses ranged from 9.6 to 41.1 (mean f SD 23.0 f 11.2) mg/24 h (0.14 to 0.82, 0.44 f 0.26 mg/ kg/24 h, Table 2 ). Excretion depended mainly on the dose of L1 (P = .003; Fig 1) . The correlation with serum ferritin was poor (P > .1). Before the trial the mean UIE in these patients at a DFX daily dose of 40 to 50 mg/kg was 0.42 f 0.32 mg/24 h ( Table 2 ). The effect of the frequency of L1 administration on UIE was variable. To evaluate it, the same daily dose of L1 was administered in four divided doses instead of two. More frequent administration caused substantial increase in urine iron in patients 2,5, and 8 (Fig
Urinary iron excretion (UIE).
2), but in four of the other patients tested, excretion was slightly greater with the twice daily regime.
Serum ferritin values decreased in 7 of the 10 patients (1,3,6,8,9, 10, and 11) by up to 42% of the original pretrial values, increased by 43% in patient 2, and remained unchanged in patients 4 and 5 (Fig 3) . The mean serum ferritin at the beginning of the trial was 5,549 +. 3, 333 (range, 1,000 to 9,580) pg/L and at the end of the trial was 4,126 f 2,278 (range, 738 to 7,435) pg/L. The overall decline in serum ferritin was significant using t-test for paired samples (P < .05).
The initial NTBI values ranged from 3.6 to 9.0 (6.1 f 1.6) pmol/L. The level decreased in eight patients after 3 to 6 months of L1 therapy. The final values measured at least 12 hours after the previous dose of L1 ranged from 3.8 to 5.4 (4.5 f 0.5) pmol/L. This final mean is sigflificantly lower (P < .005) than the initial mean NTBI. However, both means (initial and final) were significantly higher (P < .001 and P < .05 respectively) than the mean NTBI (3.7 f 2.0 pmol/L) estimated on blood samples taken at least 12 hours after the end of the previous DFX infusion in a group of 38 TM patients receiving regular chelation with DFX.
All patients maintained normal blood count throughout the trial except for patient 7, who developed agranulocytosis of sudden onset in the beginning of week 12 of the treatment and 6 weeks after being on a full dose (105 mg/kg) of L1. The patient was being seen once weekly and presented with generalized weakness, lowgrade fever, and sore throat. The drug was immediately withdrawn and she was admitted to a hospital and administered intensive treatment with broad spectrum antibiotics. She showed piogressive clinical improvement over the subsequent 3 weeks, but her neutrophil count remained low ( < 0.5 x 109/L) for 7 weeks. Details of this patient are to be reported e1~ewhere.l~ Liver function. There was no significant difference (paired t-test, P > .05) between serum aspartate transaminase (AST) levels at the start of the trial and those measured at the end of the trial. Three patients (3,4, and 6) showed a substantial decrease in serum AST levels from higher pretrial values (Fig 4) . Five patients (1, 5, 6, 7 , and Serum ferritin.
NTBZ.
Hematologic changes.
For personal use only. lo), three of whom were anti-hepatitis C virus (HCV) positive (Table I) , developed a transient fluctuating increase of serum AST shortly after starting the treatment with L,. This eventually settled in all of the patients (Fig 5) .
Serum zinc levels decreased in four patients to subnormal levels ( < 11.5 pmol/L) (Fig 6) . This decrease was accompanied by an increase ( > 9 pmol) in 24-hour urinary zinc excretion (UZE) in eight patients ( frequency of LI administration on UZE in the indivjdual patient was similar to that observed for UIE ( Table 2) . It is of interest that in three patients, UZE also increased above 9 pmol when DFX was used by these patients before the trial ( Table 2) The drug was generally well tolerated by the patients. However, 3 patients (3, 7, and 9) developed nausea on starting the treatment or on increasing the dose of LI that lasted for few days only and required no treatment. One patient complained of loose bowel motions beginning 1 week after the commencement of Ll. Stools were negative for microorganisms and the problem settled spontaneously 6 weeks later. Three patients (1, 6, and 9) had some form of musculoskeletal symptoms. Patient 1 complained of generalized muscular stiffness that was worse in the morning that began 4 months after starting treatment and lasted for 6 weeks before resolving spontaneously. This patient was negative for RhF and ANF throughout the trial. Patient 6 developed two episodes of generalized musculoskeletal pain with low-grade fever and epigastric pain. The first episode began 4 weeks after starting Ll and the second 2 weeks later. Each episode lasted for 24 hours only and resolved spontaneously, leaving no residual symptoms. RhF was positive at the outset of the trial with a titre of 1/320, which decreased 6 months later to 1/80. ANF was negative in the first 8 months and has then become weakly positive with a titre of 1/40. Patient 9 developed generalized muscular pain 9 months after startMusculoskeletal symptoms. ing Ll treatment that became progressively worse over the next 4 weeks. When L1 was temporarily withheld, the pain disappeared completely within 48 hours and reappeared, but to a lesser degree, when L1 was restarted at a full dose. RhF and ANF were negative throughout the trial.
Gastrointestinal symptoms.
At the beginning of the trial, two patients showed positive serum RhF (titres: 1/80 and 1/320) and two patients had positive serum ANF (titres: 1/160 and 1/40). At the end of the trial, the incidence and titre of RhF was unchanged; four patients were found to have positive ANF (titres: 1/320 [one patient] and 1/40 [three patients]). There was no overall relation between the presence or absence of positive ANF or RhF tests either before or during Ll therapy and the presence of muscle or joint symptoms. To assess the significance of these results, an unselected group of patients with TM (n = 51) were checked for the presence of these autoantibodies. Nine (17.6%) were positive for RhF, but none was ANF positive.
Nine patients were heavily pigmented before the start of the trial. This was partly racial, but also secondary to iron overload. In seven of them, there was a substantial decline in skin pigmentation with noticeable lightening of skin color. This occurred mainly in the first 3 months of treatment and before there was any change in serum ferritin. Two patients (1 and 2) developed skin eruptions on the face and shoulders resembling folliculitis. Microbiologic tests on swabs taken from these lesions were negative. The eruptions lasted for 6 weeks in patient 1 and for 2 weeks in patient 2 and required no treatment. Four patients (3, 6, 7, and 9) complained of dry skin. This was accompanied by hair loss in patients 3 and 9 and later by dry and itchy skin patches in the latter. This was associated with low serum zinc levels in these patients (see above). They were started on Zn tablets 220 mg/d, which was associated with improvement in the skin lesions within 4 weeks.
Autoantibodies.
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DISCUSSION
In this trial we tested the long-term use of the iron chelating drug L1 in high doses (up to 119 mg/kg/d) in patients with p TM. The drug was generally well tolerated with no detectable changes in renal, cardiac, respiratory, retinal, or auditory function. The UIE results are consistent with previous reports.@JO The important determinant of iron excretion was the total L1 dose. The mean UIE at an L1 dose of 85 to 119 mg/kg is comparable with that achieved with DFX at a dose of 40 to 50 mg/kg (0.44 f 0.26 v 0.42 0.32 mg/kg/24 h). However, some patients achieved iron excretion comparable with that with DFX at similar doses of the two chelators (Fig 2) . We3,4,6 and Olivieri et a110 reported similar findings. In the latter study, the mean UIE was lower with L1 therapy than with subcutaneous DFX Clearly, the iron excretion of the patients will depend not only on the dose and frequency of L1 administration, but also on the iron load of the patient, and this will depend on the number of blood transfusions and previous chelation therapy.
The effect of the frequency of L1 administration on iron excretion in our present trial was variable. An increased frequency of smaller doses with the same total daily dose caused a substantial increase in urinary excretion in three patients, but had little or an opposite effect in the other five patients tested. It remains to be determined whether more frequent L1 dosing with the resultant lowering of serum peak levels of the drug would also lead to fewer side effects.
The percentage of patients having a decline in serum ferritin level was higher than previously reported. Kontoghiorghes et a16 reported no overall change in serum ferritin levels over the period of their study (1 to 15 months) in 13 patients receiving various doses of L1. Tondury et a16 reported a decline in serum ferritin levels in three of the eight patients who received L1 at a daily dose of 55 to 80 mg/kg for 4 to 10 months. Therefore, it is likely that the high L1 dose used in the present trial for a relatively long period is responsible for this result. The decrease in serum ferritin levels appeared to be greater in those with the highest initial levels (Fig 3) , but larger numbers of patients are needed to confirm this. There was also a significant decrease in the patients' NTBI levels. However, the final mean NTBI was still significantly higher than that estimated in a comparable group of DFX-treated patients. Further studies are therefore necessary to determine whether more prolonged chelation with L1 will achieve NTBI values similar to those achieved by prolonged chelation with DFX.
The musculoskeletal adverse effects observed during the course of the trial were mild and transient. These effects resembled those we7 and otherdl have previously reported. There was no relation between the presence of these symptoms and the presence of the different autoantibodies tested before or after the therapy. The changes in the liver enzyme AST were also transient and settled without discontinuation of L1 therapy. The initial fluctuating liver enzyme pattern occurred in three of four anti-HCV-positive patients and two of seven anti-HCV-negative patients. Further studies are needed on whether HCV is important to these changes in liver enzymes during L1 therapy. Similar changes have not previously been reported. Bartlett et a17 reported an increase in AST in one of their patients receiving L1. However, this was secondary to alcohol consumption and settled on abstinence.
The occurrence of agranulocytosis in one patient during the early stage of the trial highlights the potential toxicity of this drug and the need for relentless vigilance in monitoring the blood count in patients receiving L1. We have undertaken several experiments to elucidate the role of L1 in the pathogenesis of agranulocytosis in this patient. When compared with those of normal individuals, we have not found an increased sensitivity of the patient's bone marrow WBC progenitors to L1 in culture.18 These studies have suggested but not proven the presence of a weak drugdependent antimyeloid precursor IgM antibody in the For personal use only. on October 22, 2017. by guest www.bloodjournal.org From blood of the patient during agranulocytosis or convalescence." This is the second case of L1-induced agranulocytosis to be reported. The first case was a 28-year-old woman with Blackfan-Diamond anemia who also developed agranulocytosis 6 weeks after receiving L1 at a dose of 105 mg/kg. She had previously received the drug for 5 months, largely at the lower dose of 50 mg/kg. Also, in that case the marrow myeloid progenitors were not particularly sensitive to L1 in vitro.I9 Therefore, the exact mechanism of L1-induced agranulocytosis remains obscure. However, it is of interest that both were females and had been receiving L1 at the maximum doses of about 100 mg/kg/d for 6 weeks when agranulocytosis developed and both had shown serum red blood cell antibodies. In the present case, there were the alloantibodies, anti-C, anti-D, anti-Kpa, and anti-Kell, present since early childhood. In the Blackfan-Diamond patient, there was a reversible anti-Lw autoantibody.19
Although L1 is an avid iron chelator with a high binding constant, it nevertheless can bind other cations, although with a much lower affinity. No change in serum zinc levels or increase in UZE in patients receiving L1 has been reported previously. However, in the present trial, L1 administration was associated with a decrease in serum zinc levels in four of the patients. There was an increase in UZE in eight of the patients and symptoms attributable to zinc deficiency in two of them. These symptoms improved after zinc administration. However, the correlation between the amount of zinc excreted in urine and the severity of serum zinc decline was poor. Zinc excretion also increased when subcutaneous DFX was administered to these patients at a daily dose of 40 to 50 mg/kg before the trial and by a large group of patients (n = 42) with TM receiving subcutaneous DFX (unpublished data). However, none of the L1-treated patients showed low serum zinc levels before the trial and only 8 of the 42 non-L1 patients showed subnormal serum zinc levels, with none having symptoms attributable to zinc deficiency. Taken together, these observations suggest that zinc status in patients receiving L1 or DFX may be finely balanced, dietary intake being normally sufficient to prevent deficiency, except in some patients receiving a high dose (85 to 120 mg/kg) of L1 long term. The degree of zinc deficiency noted in patients treated here with L1 is minor and easily corrected. It is much less severe than that encountered in patients receiving the iron chelator diethyltriamine penta-acetic acid (DTPA).20
In conclusion, in most patients in this study, the administration of L1 as a dose in the region of 100 mg/kg/d induced iron excretion ( > O S mg/kg/d) sufficient to maintain a negative iron balance and there was an overall significant decline in serum ferritin levels. The dose and regime need to be determined in each patient, as there has been substantial variation in response to different dose regimens. All 11 patients stated a clear preference for using L1 compared with subcutaneous DFX and the patients' apparent compliance with the drug throughout the trial was excellent. As yet, only a few possible side effects have been noted. The results here show for the first time that these side effects include mild zinc deficiency in some patients and report agranulocytosis in a TM patient. As L1 has the potential of causing agranulocytosis, it is necessary to closely monitor the blood count and, in particular, the WBC count in patients receiving it.
